Open access
Jul 2026
Immunotherapeutic control of MHC I-heterogeneous tumors to minimize therapy resistance 2307892
It is demonstrated for the first time in a controlled setting with mixed MHC I+/- tumors that anti-PD-1 therapy selects for outgrowth of MHC I-deficient tumor cells, dependent on CD8 T cells.
Abigail Mende, Sooyun Cho, Chenyu Zhang et al.
· Journal of Immunology · 0 citations